Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations

INTRODUCTION: Patients with advanced lung adenocarcinoma harboring epidermal growth factor receptor (EGFR)-activating mutations have good response rate and longer progression-free survival (PFS) when treated with the tyrosine kinase inhibitors (TKI) compared with platinum-based chemotherapy. However...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Tu, Chih-Yen, Chen, Chuan-Mu, Liao, Wei-Chih, Wu, Biing-Ru, Chen, Chih-Yu, Chen, Wei-Chun, Hsia, Te-Chun, Cheng, Wen-Chien, Chen, Chia-Hung
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5966263/
https://ncbi.nlm.nih.gov/pubmed/29849936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24386
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados